Switch to:
More From Other Websites
Novartis treatment for vision loss meets goals in study Feb 27 2015
The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Feb 27 2015
Up and Down the Ladder: The Latest Comings & Goings at Alkermes, Charles River Labs and… Feb 27 2015
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 27 2015
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
Lightning Round: This group goes higher tomorrow Feb 25 2015
Cramer Remix: Where's the Nasdaq bubble? Feb 23 2015
Cramer: Watch out - regulators are gunning for these stoc... Feb 23 2015
Lightning Round: Don't listen to this CEO Feb 23 2015
Regeneron Shares Reach Full Valuation Feb 23 2015
Lightning Round: This stock's got to get game back Feb 20 2015
FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Feb 20 2015
Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Feb 19 2015
Update: Regeneron: Too Much Excitement About Eylea News? Feb 19 2015
Regeneron Pharms downgraded by ROTH Capital Feb 19 2015
REGENERON PHARMACEUTICALS INC Financials Feb 19 2015
Regeneron Tops Roche in Eye Drug Study That May Boost Sales Feb 19 2015
Regeneron: Need fair drug prices Feb 19 2015
NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept)... Feb 18 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK